Active pharmaceutical ingredient and excipients

Formulation of the drug product, which includes active pharmaceutical ingredients and excipients, into final form suitable to be administered to patients... 

Most drugs that are prescribed to us are formulated with active pharmaceutical ingredients and excipients. The formulations of selected drugs are presented in Exhibit 5.11. According to the US Pharmacopoeia and National Formulary definition, excipients are any component, other than the active substance(s), intentionally added to the formulation of a dosage form. There are many reasons for the addition of excipients ... 

Another advantage of SS-NMR is that the observed chemical shift differences between polymorphs can be related to particular molecular sites based on known assignments (see Figure 6). Site-specific mobility can also be determined by probing the relaxation properties of the compound. This is an important application, since mobility is usually related to polymorphic interconversions and solid-state reactions.94 Solid-state reactions between active pharmaceutical ingredients and excipients can also be followed by SS-NMR. The study of polymorphic transitions can be performed by variable temperature experiments. 

A general term used to denote starting materials (active pharmaceutical ingredients and excipients), reagents, solvents, process aids, intermediates, packaging materials and labelling materials. 

Li, W. and Worosila, G. D. Quantitation of active pharmaceutical ingredients and excipients in powder blends using designed multivariate calibration models by near-infrared spectroscopy. Int. J. Pharm. 295 213-219, 2005. 

The preferred and easiest intake of medicines is by oral ingestion in the form of tablets. Tablets today contain a combination of an active pharmaceutical ingredient and a (polymer) excipient-the inactive ingredient that delivers the pharmaceutical active... 

In Section 8.2, the aim of analysis is emphasized especially for the API (active pharmaceutical ingredient) and the drug product. The workflows and the rationale at major decision points during synthetic processing steps where HPLC can be applied in process development are elaborated upon. For example, a fast method is needed to monitor reaction conversion of two components. However, a more complex method would be needed for stability-indicating purposes where multiple degradation products, synthetic by-products, and excipient peaks need to be resolved from the active pharmaceutical ingredient. 

Differences between methods from Tier 1 through Tier 3 are due to the extent of validation of the analytical figures of merit that is performed [3]. During early development of the active pharmaceutical ingredient and early dosage form development, emphasis is placed on speed and quantitation of the API. At this stage, methods rely on the use of short columns, fast flows, and very minimum validation to quickly identify the most desirable synthetic route for the API that will produce an adequate impurity profile (overall yield may not be optimized at this stage) and most desirable prototype formulations and excipients that will ultimately lead to the selection of the final formula-... 

On the left part of the screen, you can select the active pharmaceutical ingredient or excipient category (in the case of the active pharmaceutical ingredients, a letter of the alphabet is also displayed) and open the desired spectra sheet by clicking on it. 

The Committee for Proprietary Medicinal Products [8] applied the BCS, with certain requirements, to dispense with bioequivalency tests if the active pharmaceutical ingredient is class I and the in vitro dissolution of the finished dosage form is fast [9], An active substance is considered highly soluble if the amount contained in the HDS of an IR product is dissolved in 250 ml of each of three buffers within the range of pH 1-8 at 37°C (e.g., pH 1.0, 4.6, and 6.8). There should be linear and complete absorption, which indicates HP to reduce the possibility of an IR dosage form influencing the bioavailability [8], The similarity of the dissolution profiles of the test and reference products is demonstrated in each of three buffers within the range of pH 1-8 at 37°C (e.g., pH 1.0,4.6, and 6.8). If there is rapid dissolution of the product, where at least 85% of the active substance is dissolved within 15 min, no further comparison of the test and reference is required. Further requirements include that excipients be well established and have no interaction with the pharmacokinetics of the active substance and that the method of manufacture of finished product... 

Pharmaceuticals, for the purpose of this book, means chemical compounds that are used in pharmaceutical production. This can comprise the active ingredient, which is also called active pharmaceutical ingredient (API) or drug substance or drug product and the inert pharmaceutical ingredients (excipients) that are used to formulate a drug product in the form of tablets, capsules, ointments, creams, lotions, parenterals, inhalers, and a variety of drug delivery systems. 

Drug products contain both drug substance (sometimes referred to as the Active Pharmaceutical Ingredient [API]) and excipients. The resultant biological, chemical and physical properties of the dmg product are directly dependent on the excipients chosen, their concentration and interactions with the API [1]. 

Chemical compound homogeneity is an important issue for pharmaceutical sohd forms. A classical spectrometer integrates the spatial information. In solid form analysis, use of a mean spectrum on a surface can be a drawback. For example, in the pharmaceutical industry it is important to map the distribution of active ingredients and excipients in a tablet so as to reveal physical interaction between the compounds and help to solve homogeneity issues. Spectroscopic imaging techniques that visualize chemical component distribution are thus of great interest to the pharmaceutical community. 

---